What is Ace Vision Group?
Ace Vision Group, Inc. is an innovative ophthalmic laser device company dedicated to developing touchless eye laser therapy for age-related vision loss, specifically targeting presbyopia, a condition affecting billions globally. Their proprietary Laser Scleral Microporation (LSM) technology is currently in pilot clinical trials outside the United States, with the aim of transforming eye care. The company actively collaborates with leading eye care professionals to refine their treatments and improve patient outcomes. While awaiting FDA approval, Ace Vision Group is engaging healthcare providers and potential patients to advance this pioneering therapy.
How much funding has Ace Vision Group raised?
Ace Vision Group has raised a total of $42.7M across 2 funding rounds:
Series A
$13.3M
Series B
$29.4M
Series A (2021): $13.3M with participation from Picerne Real Estate Group
Series B (2025): $29.4M, investors not publicly disclosed
Key Investors in Ace Vision Group
Picerne Real Estate Group
Picerne Real Estate Group, a notable entity, participated in Ace Vision Group's Series A funding, indicating a potential interest in ventures with long-term growth potential.
What's next for Ace Vision Group?
With a major enterprise-level funding context, Ace Vision Group is poised for significant scaling and further development of its groundbreaking LSM technology. The recent strategic investment will likely accelerate the progression of their pilot clinical trials and support efforts towards achieving FDA approval. Future endeavors will focus on expanding market reach, potentially through strategic partnerships, and preparing for commercialization. The company's commitment to collaborating with healthcare professionals suggests a strategy focused on clinical validation and market adoption, positioning Ace Vision Group as a key player in the future of ophthalmic treatments.
See full Ace Vision Group company page
